Finance

Lists
Q3 2026 earnings • in 2 days
See details
PACS:NYSE
PACS Group Inc
$45.58
-4.66%
(-2.23) 1D
$46.00
+0.91% (+0.42)
After hours
Closed: Nov 2, 4:00:04 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PACS...
Open
$47.77
High
$47.91
Low
$45.45
Mkt. cap
7.22B
Avg. vol.
804.26K
Volume
874.90K
P/E ratio
27.31
52-wk high
$50.38
52-wk low
$10.31
EPS
$1.67
Shares outstanding
158.34M
No. of employees
47K
Open
$47.77
High
$47.91
Low
$45.45
Mkt. cap
7.22B
Avg. vol.
804.26K
Volume
874.90K
P/E ratio
27.31
52-wk high
$50.38
52-wk low
$10.31
EPS
$1.67
Shares outstanding
158.34M
No. of employees
47K
News stories
From web sources and news partners
About PACS Group Inc
CEO-
Employees47.5K
Founded2013
HeadquartersSalt Lake City, Utah, United States
SectorHealth care provider
Websitepacs.com
Analyst ratings
Based on 5 analysts giving stock ratings to PACS in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for PACS in the last 3 months.
Highest
Current $45.58
$60.00 (+31.64%)
Average
$58.00 (+27.25%)
Lowest
$57.00 (+25.05%)
Analyst
Recommendation
Action
Price target
Projected
Date
A.J. Rice
UBS
Buy
Maintained
$60.00
+31.6%
10/12/2026
Benjamin Rossi
J.P. Morgan
Buy
Reiterated
$58.00
+27.2%
09/08/2026
David S Macdonald
Truist Financial
Buy
Maintained
-
-
09/02/2026
Michael Wiederhorn
Oppenheimer
Buy
Maintained
$57.00
+25.1%
08/10/2026
Ben Hendrix
RBC Capital
Buy
Reiterated
$57.00
+25.1%
08/05/2026
Jailendra Singh
Truist Financial
Buy
Reiterated
$52.00
+14.1%
06/15/2026
Next call in 38:27:21
Wed, Nov 4, 11:30 AM
Fiscal period
Q3 2026
- / $0.58
Revenue / Est. (USD)
- / 1.46B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.34B
1.36B
1.42B
1.43B
Cost of goods sold
1.13B
1.12B
1.16B
1.17B
Cost of revenue
1.13B
1.12B
1.16B
1.17B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
112.44M
123.29M
122.45M
124.74M
Operating expense
126.84M
138.67M
140.52M
144.86M
Total operating expenses
1.26B
1.26B
1.30B
1.32B
Operating income
86.27M
94.69M
120.04M
109.33M
Other non operating income
-956.00K
-99.00K
-330.00K
1.82M
EBT including unusual items
76.30M
86.81M
113.74M
105.84M
EBT excluding unusual items
76.30M
86.81M
113.74M
105.84M
Income tax expense
23.97M
27.03M
33.07M
29.49M
Effective tax rate
31.41%
31.13%
29.07%
27.86%
Other operating expenses
-
-
-
-
Net income
52.41M
59.70M
80.70M
76.37M
Net profit margin
3.90%
4.40%
5.68%
5.35%
Earnings per share
0.45
0.57
0.64
0.63
Interest and investment income
-
-
-
-
Interest expense
-8.53M
-8.58M
-6.42M
-6.04M
Net interest expenses
-8.53M
-8.58M
-6.42M
-6.04M
Depreciation and amortization charges
14.40M
15.38M
18.08M
20.12M
EBITDA
100.67M
110.07M
138.11M
129.45M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps